Market research
IRWD Ironwood Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 709M
- Analyst target
- 6.1
- Dividend yield
- Not available
- Beta
- 0.21
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US46333X1081
- Market cap
- 709M
- Analyst target
- 6.1
- Dividend yield
- Not available
- Beta
- 0.21
About
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IRWD discussion.
5 years, 4 months ago
Ironwood Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 11.1% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.5.
Ironwood Pharmaceuticals, Inc's total revenue sank by 7.6% to $117M since the same quarter in the previous year.
Its net income has dropped by 9.7% to $43M since the same quarter in the previous year.
Finally, its free cash flow grew by 106.7% to $51M since the same quarter in the previous year.
Based on the above factors, Ironwood Pharmaceuticals, Inc gets an overall score of 3/5.